81 FR 7352 - National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 81, Issue 28 (February 11, 2016)
National Institutes of Health
Federal Register Volume 81, Issue 28 (February 11, 2016)
| Page Range | 7352-7352 | |
| FR Document | 2016-02709 |
[Federal Register Volume 81, Number 28 (Thursday, February 11, 2016)] [Notices] [Page 7352] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-02709] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; Career Award and Conference Grant Review (2016/05). Date: March 18, 2016. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Mark Martin, Ph.D., Scientific Review Officer, 6707 Democracy Boulevard, Suite 920, Bethesda, MD 20892, (240) 447- 2148, [email protected]. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; P41 BTRC review (2016/05). Date: March 23-25, 2016. Time: 6:00 p.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, MA 02114. Contact Person: Dennis Hlasta, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 451-4794, [email protected]. Dated: February 4, 2016. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016-02709 Filed 2-10-16; 8:45 am] BILLING CODE 4140-01-P
![7352 Federal Register / Vol. 81, No. 28 / Thursday, February 11, 2016 / Notices
to lead to an adverse effect on the safety interested in making formal oral confidential trade secrets or commercial
or effectiveness of the drug or category presentations should notify the contact property such as patentable material,
of drugs, taking into account the risks person and submit a brief statement of and personal information concerning
and benefits to patients, or the drug is the general nature of the evidence or individuals associated with the grant
compounded in accordance with all arguments they wish to present, the applications, the disclosure of which
applicable conditions identified on the names and addresses of proposed would constitute a clearly unwarranted
list as conditions that are necessary to participants, and an indication of the invasion of personal privacy.
prevent the drug or category of drugs approximate time requested to make Name of Committee: National Institute of
from presenting such demonstrable their presentation on or before February Biomedical Imaging and Bioengineering
difficulties (see section 503B(a)(6)(A) 24, 2016. Time allotted for each Special Emphasis Panel; Career Award and
and (B) of the FD&C Act). presentation may be limited. If the Conference Grant Review (2016/05).
FDA will discuss with the committee number of registrants requesting to Date: March 18, 2016.
drugs proposed for inclusion on the speak is greater than can be reasonably Time: 9:00 a.m. to 6:00 p.m.
section 503A bulk drug substances list Agenda: To review and evaluate grant
accommodated during the scheduled applications.
and on the demonstrably difficult to open public hearing session, FDA may Place: National Institutes of Health, Two
compound list under sections 503A and conduct a lottery to determine the Democracy Plaza, Suite 920, 6707 Democracy
503B of the FD&C Act. speakers for the scheduled open public Boulevard, Bethesda, MD 20892 (Virtual
Agenda: On March 8, 2016, the hearing session. The contact person will Meeting).
committee will discuss six bulk drug notify interested persons regarding their Contact Person: Mark Martin, Ph.D.,
substances nominated for inclusion on request to speak by February 25, 2016. Scientific Review Officer, 6707 Democracy
the section 503A bulk drug substances Persons attending FDA’s advisory Boulevard, Suite 920, Bethesda, MD 20892,
list. FDA will discuss the following (240) 447–2148, mark.martin@mail.nih.gov.
committee meetings are advised that the
nominated bulk drug substances: Agency is not responsible for providing Name of Committee: National Institute of
Quinacrine hydrochloride, boswellia, Biomedical Imaging and Bioengineering
access to electrical outlets. Special Emphasis Panel; P41 BTRC review
aloe vera 200:1 freeze dried, D-ribose, FDA welcomes the attendance of the (2016/05).
chondroitin sulfate, and acetyl-L- public at its advisory committee Date: March 23–25, 2016.
carnitine. The nominators of these meetings and will make every effort to Time: 6:00 p.m. to 1:00 p.m.
substances will be invited to make a accommodate persons with disabilities. Agenda: To review and evaluate grant
short presentation supporting the If you require accommodations due to a applications.
nomination. disability, please contact Cindy Hong at Place: Wyndham Boston Beacon Hill, 5
On March 9, 2016, the committee will least 7 days in advance of the meeting. Blossom Street, Boston, MA 02114.
discuss two categories of drug products Contact Person: Dennis Hlasta, Ph.D.,
FDA is committed to the orderly
nominated for the list of drug products Scientific Review Officer, National Institute
conduct of its advisory committee of Biomedical Imaging and Bioengineering,
that present demonstrable difficulties meetings. Please visit our Web site at National Institutes of Health, 6707
for compounding. These categories of http://www.fda.gov/Advisory Democracy Blvd., Bethesda, MD 20892, (301)
drug products are metered dose inhalers Committees/AboutAdvisoryCommittees/ 451–4794, dennis.hlasta@nih.gov.
and dry powder inhalers. The ucm111462.htm for procedures on
nominators who nominated the category Dated: February 4, 2016.
public conduct during advisory David Clary,
of drugs or specific drug products in the committee meetings.
category will be invited to make a short Program Analyst, Office of Federal Advisory
Notice of this meeting is given under
presentation supporting the nomination. Committee Policy.
the Federal Advisory Committee Act (5
FDA intends to make background U.S.C. app. 2). [FR Doc. 2016–02709 Filed 2–10–16; 8:45 am]
material available to the public no later BILLING CODE 4140–01–P
than 2 business days before the meeting. Dated: February 8, 2016.
If FDA is unable to post the background Jill Hartzler Warner,
material on its Web site prior to the Associate Commissioner for Special Medical DEPARTMENT OF HEALTH AND
meeting, the background material will Programs. HUMAN SERVICES
be made publicly available at the [FR Doc. 2016–02786 Filed 2–8–16; 4:15 pm]
location of the advisory committee BILLING CODE 4164–01–P
National Institutes of Health
meeting, and the background material
National Institute on Aging; Notice of
will be posted on FDA’s Web site after
DEPARTMENT OF HEALTH AND Closed Meeting
the meeting. Background material is
available at http://www.fda.gov/ HUMAN SERVICES Pursuant to section 10(d) of the
AdvisoryCommittees/Calendar/ Federal Advisory Committee Act, as
default.htm. Scroll down to the National Institutes of Health amended (5 U.S.C. App.), notice is
appropriate advisory committee meeting hereby given of the following meeting.
National Institute of Biomedical
link. The meeting will be closed to the
Imaging and Bioengineering; Notice of
Procedure: Interested persons may public in accordance with the
Closed Meetings
present data, information, or views, provisions set forth in sections
orally or in writing, on issues pending Pursuant to section 10(d) of the 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
before the committee. Written Federal Advisory Committee Act, as as amended. The grant applications and
mstockstill on DSK4VPTVN1PROD with NOTICES
submissions may be made to the contact amended (5 U.S.C. App.), notice is the discussions could disclose
person on or before March 1, 2016. Oral hereby given of the following meetings. confidential trade secrets or commercial
presentations from the public will be The meetings will be closed to the property such as patentable material,
scheduled between approximately 11 public in accordance with the and personal information concerning
a.m. to 11:15 a.m. and 3:15 p.m. to 3:30 provisions set forth in sections individuals associated with the grant
p.m. on March 8, 2016, and between 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., applications, the disclosure of which
approximately 11:30 a.m. to 12 noon on as amended. The grant applications and would constitute a clearly unwarranted
March 9, 2016. Those individuals the discussions could disclose invasion of personal privacy.
VerDate Sep<11>2014 16:52 Feb 10, 2016 Jkt 238001 PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\11FEN1.SGM 11FEN1](https://thefederalregister.org/doc/81_FR_7380/page/1.svg)
Document Created: 2016-02-11 00:03:25
Document Modified: 2016-02-11 00:03:25
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | March 18, 2016. | |
| FR Citation | 81 FR 7352 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR